<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36936993</PMID><DateRevised><Year>2023</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-889X</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in molecular biosciences</Title><ISOAbbreviation>Front Mol Biosci</ISOAbbreviation></Journal><ArticleTitle>Untargeted analysis in post-COVID-19 patients reveals dysregulated lipid pathways two years after recovery.</ArticleTitle><Pagination><StartPage>1100486</StartPage><MedlinePgn>1100486</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1100486</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmolb.2023.1100486</ELocationID><Abstract><AbstractText><b>Introduction:</b> Similar to what it has been reported with preceding viral epidemics (such as MERS, SARS, or influenza), SARS-CoV-2 infection is also affecting the human immunometabolism with long-term consequences. Even with underreporting, an accumulated of almost 650 million people have been infected and 620 million recovered since the start of the pandemic; therefore, the impact of these long-term consequences in the world population could be significant. Recently, the World Health Organization recognized the post-COVID syndrome as a new entity, and guidelines are being established to manage and treat this new condition. However, there is still uncertainty about the molecular mechanisms behind the large number of symptoms reported worldwide. <b>Aims and Methods:</b> In this study we aimed to evaluate the clinical and lipidomic profiles (using non-targeted lipidomics) of recovered patients who had a mild and severe COVID-19 infection (acute phase, first epidemic wave); the assessment was made two years after the initial infection. <b>Results:</b> Fatigue (59%) and musculoskeletal (50%) symptoms as the most relevant and persistent. Functional analyses revealed that sterols, bile acids, isoprenoids, and fatty esters were the predicted metabolic pathways affected in both COVID-19 and post-COVID-19 patients. Principal Component Analysis showed differences between study groups. Several species of phosphatidylcholines and sphingomyelins were identified and expressed in higher levels in post-COVID-19 patients compared to controls. The paired analysis (comparing patients with an active infection and 2&#xa0;years after recovery) show 170 dysregulated features. The relationship of such metabolic dysregulations with the clinical symptoms, point to the importance of developing diagnostic and therapeuthic markers based on cell signaling pathways.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 L&#xf3;pez-Hern&#xe1;ndez, Oropeza-Valdez, Garc&#xed;a Lopez, Borrego, Murgu, Valdez, L&#xf3;pez and Mon&#xe1;rrez-Espino.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>L&#xf3;pez-Hern&#xe1;ndez</LastName><ForeName>Yamil&#xe9;</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>CONACyT-Metabolomics and Proteomics Laboratory, Academic Unit of Biological Sciences, Autonomous University of Zacatecas, Zacatecas, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oropeza-Valdez</LastName><ForeName>Juan Jos&#xe9;</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Metabolomics and Proteomics Laboratory, Academic Unit of Biological Sciences, Autonomous University of Zacatecas, Zacatecas, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a Lopez</LastName><ForeName>David Alejandro</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Doctorado en Ciencias B&#xe1;sicas, Universidad Aut&#xf3;noma de Zacatecas, Zacatecas, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borrego</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Departamento de Epidemiolog&#xed;a, Hospital General de Zona #1 "Emilio Varela Luj&#xe1;n", Instituto Mexicano del Seguro Social, Centro, Zacatecas, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murgu</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Waters Technologies of Brazil, Alameda Tocantins, Barueri, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valdez</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Waters Corporation, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez</LastName><ForeName>Jes&#xfa;s Adri&#xe1;n</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>MicroRNAs and Cancer Laboratory, Academic Unit of Biological Sciences, Autonomous University of Zacatecas, Zacatecas, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mon&#xe1;rrez-Espino</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Health Research, Christus Muguerza del Parque Hospital Chihuahua, University of Monterrey, San Pedro Garza Garc&#xed;a, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Mol Biosci</MedlineTA><NlmUniqueID>101653173</NlmUniqueID><ISSNLinking>2296-889X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">lipidomics</Keyword><Keyword MajorTopicYN="N">long covid</Keyword><Keyword MajorTopicYN="N">metabolite</Keyword><Keyword MajorTopicYN="N">metabolomics</Keyword><Keyword MajorTopicYN="N">post-COVID-19</Keyword></KeywordList><CoiStatement>MM and JV are employed by Waters Corporation. The remaining authors declare that the research was conducted in the absence of any commercial of financial relationships that could be seen as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>20</Day><Hour>3</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36936993</ArticleId><ArticleId IdType="pmc">PMC10022496</ArticleId><ArticleId IdType="doi">10.3389/fmolb.2023.1100486</ArticleId><ArticleId IdType="pii">1100486</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Acosta-Ampudia Y., Monsalve D. M., Rojas M., Rodr&#xed;guez Y., Gallo J. E., Salazar-Uribe J. C., et al. (2021). COVID-19 convalescent plasma composition and immunological effects in severe patients. J. Autoimmun. 118, 102598. 10.1016/j.jaut.2021.102598</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2021.102598</ArticleId><ArticleId IdType="pmc">PMC7826092</ArticleId><ArticleId IdType="pubmed">33524876</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Xie Y., Bowe B. (2021). High-dimensional characterization of post-acute sequelae of COVID-19. Nature 594, 259&#x2013;264. 10.1038/s41586-021-03553-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavez J. A., Summers S. A. (2012). A ceramide-centric view of insulin resistance. Cell Metab. 15, 585&#x2013;594. 10.1016/j.cmet.2012.04.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2012.04.002</ArticleId><ArticleId IdType="pubmed">22560211</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W., Yao M., Chen M., Ou Z., Yang Q., He Y., et al. (2022). Using an untargeted metabolomics approach to analyze serum metabolites in COVID-19 patients with nucleic acid turning negative. Front. Pharmacol. 13, 964037. 10.3389/fphar.2022.964037</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.964037</ArticleId><ArticleId IdType="pmc">PMC9449332</ArticleId><ArticleId IdType="pubmed">36091834</ArticleId></ArticleIdList></Reference><Reference><Citation>Collaborators G. B. O. D. L. C., Wulf Hanson S., Abbafati C., Aerts J. G., Al-Aly Z., Ashbaugh C., et al. (2022). Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA 328, 1604&#x2013;1615. 10.1001/jama.2022.18931</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18931</ArticleId><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Cowart L. A. (2010). A novel role for sphingolipid metabolism in oxidant-mediated skeletal muscle fatigue. Focus on &#x201c;Sphingomyelinase stimulates oxidant signaling to weaken skeletal muscle and promote fatigue&#x201d;. Am. J. Physiology-Cell Physiology 299, C549&#x2013;C551. 10.1152/ajpcell.00236.2010</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00236.2010</ArticleId><ArticleId IdType="pubmed">20573998</ArticleId></ArticleIdList></Reference><Reference><Citation>Danieli-Betto D., Germinario E., Esposito A., Megighian A., Midrio M., Ravara B., et al. (2005). Sphingosine 1-phosphate protects mouse extensor digitorum longus skeletal muscle during fatigue. Am. J. Physiol. Cell Physiol. 288, C1367&#x2013;C1373. 10.1152/ajpcell.00246.2004</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00246.2004</ArticleId><ArticleId IdType="pubmed">15659717</ArticleId></ArticleIdList></Reference><Reference><Citation>Declaration of Helsinki (1976). Recommendations guiding medical doctors in biomedical research involving human subjects. Ugeskr. Laeger 138, 399&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">1251519</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-De-Las-Pe&#xf1;as C., Palacios-Ce&#xf1;a D., G&#xf3;mez-Mayordomo V., Florencio L. L., Cuadrado M. L., Plaza-Manzano G., et al. (2021). Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: A systematic review and meta-analysis. Eur. J. Intern Med. 92, 55&#x2013;70. 10.1016/j.ejim.2021.06.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2021.06.009</ArticleId><ArticleId IdType="pmc">PMC8206636</ArticleId><ArticleId IdType="pubmed">34167876</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippatou A. G., Moniruzzaman M., Sotirchos E. S., Fitzgerald K. C., Kalaitzidis G., Lambe J., et al. (2021). Serum ceramide levels are altered in multiple sclerosis. Mult. Scler. 27, 1506&#x2013;1519. 10.1177/1352458520971816</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458520971816</ArticleId><ArticleId IdType="pmc">PMC8200368</ArticleId><ArticleId IdType="pubmed">33307993</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghini V., Meoni G., Pelagatti L., Celli T., Veneziani F., Petrucci F., et al. (2022). Profiling metabolites and lipoproteins in COMETA, an Italian cohort of COVID-19 patients. PLOS Pathog. 18, e1010443. 10.1371/journal.ppat.1010443</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010443</ArticleId><ArticleId IdType="pmc">PMC9022834</ArticleId><ArticleId IdType="pubmed">35446921</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez Marti J. L., Wells A., Brufsky A. M. (2021). Dysregulation of the mevalonate pathway during SARS-CoV-2 infection: An in silico study. J. Med. Virol. 93, 2396&#x2013;2405. 10.1002/jmv.26743</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26743</ArticleId><ArticleId IdType="pmc">PMC9553089</ArticleId><ArticleId IdType="pubmed">33331649</ArticleId></ArticleIdList></Reference><Reference><Citation>Guntur V. P., Nemkov T., De Boer E., Mohning M. P., Baraghoshi D., Cendali F. I., et al. (2022). Signatures of mitochondrial dysfunction and impaired fatty acid metabolism in plasma of patients with post-acute sequelae of COVID-19 (PASC). Metabolites 12, 1026. 10.3390/metabo12111026</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/metabo12111026</ArticleId><ArticleId IdType="pmc">PMC9699059</ArticleId><ArticleId IdType="pubmed">36355108</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao Y., Zhang Z., Feng G., Chen M., Wan Q., Lin J., et al. (2021). Distinct lipid metabolic dysregulation in asymptomatic COVID-19. iScience 24, 102974. 10.1016/j.isci.2021.102974</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2021.102974</ArticleId><ArticleId IdType="pmc">PMC8356725</ArticleId><ArticleId IdType="pubmed">34396083</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrera-Van Oostdam A. S., Casta&#xf1;eda-Delgado J. E., Oropeza-Valdez J. J., Borrego J. C., Mon&#xe1;rrez-Espino J., Zheng J., et al. (2021). Immunometabolic signatures predict risk of progression to sepsis in COVID-19. PLOS ONE 16, e0256784. 10.1371/journal.pone.0256784</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0256784</ArticleId><ArticleId IdType="pmc">PMC8405033</ArticleId><ArticleId IdType="pubmed">34460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Holstein S. A., Hohl R. J. (2004). Isoprenoids: Remarkable diversity of form and function. Lipids 39, 293&#x2013;309. 10.1007/s11745-004-1233-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11745-004-1233-3</ArticleId><ArticleId IdType="pubmed">15357017</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirwan J. A., Gika H., Beger R. D., Bearden D., Dunn W. B., Goodacre R., et al. (2022). Quality assurance and quality control reporting in untargeted metabolic phenotyping: mQACC recommendations for analytical quality management. Metabolomics 18, 70. 10.1007/s11306-022-01926-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11306-022-01926-3</ArticleId><ArticleId IdType="pmc">PMC9420093</ArticleId><ArticleId IdType="pubmed">36029375</ArticleId></ArticleIdList></Reference><Reference><Citation>Leistner R., Schroeter L., Adam T., Poddubnyy D., Stegemann M., Siegmund B., et al. (2022). Corticosteroids as risk factor for COVID-19-associated pulmonary aspergillosis in intensive care patients. Crit. Care 26, 30. 10.1186/s13054-022-03902-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-022-03902-8</ArticleId><ArticleId IdType="pmc">PMC8796178</ArticleId><ArticleId IdType="pubmed">35090528</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F., Fu L., Liu X., Liu X. A., Liang Y., Lv Y., et al. (2022). Serum metabolomic abnormalities in survivors of non-severe COVID-19. Heliyon 8, e10473. 10.1016/j.heliyon.2022.e10473</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2022.e10473</ArticleId><ArticleId IdType="pmc">PMC9433334</ArticleId><ArticleId IdType="pubmed">36065322</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S., Park Y., Duraisingham S., Strobel F. H., Khan N., Soltow Q. A., et al. (2013). Predicting network activity from high throughput metabolomics. PLOS Comput. Biol. 9, e1003123. 10.1371/journal.pcbi.1003123</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1003123</ArticleId><ArticleId IdType="pmc">PMC3701697</ArticleId><ArticleId IdType="pubmed">23861661</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Hern&#xe1;ndez Y., Mon&#xe1;rrez-Espino J., Oostdam A. H., Delgado J. E. C., Zhang L., Zheng J., et al. (2021). Targeted metabolomics identifies high performing diagnostic and prognostic biomarkers for COVID-19. Sci. Rep. 11, 14732. 10.1038/s41598-021-94171-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-94171-y</ArticleId><ArticleId IdType="pmc">PMC8290000</ArticleId><ArticleId IdType="pubmed">34282210</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S., Wegman-Ostrosky T., Perelman C., Sepulveda R., Rebolledo P. A., Cuapio A., et al. (2021). More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci. Rep. 11, 16144. 10.1038/s41598-021-95565-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik P., Patel K., Pinto C., Jaiswal R., Tirupathi R., Pillai S., et al. (2022). Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)-A systematic review and meta-analysis. J. Med. Virol. 94, 253&#x2013;262. 10.1002/jmv.27309</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27309</ArticleId><ArticleId IdType="pmc">PMC8662132</ArticleId><ArticleId IdType="pubmed">34463956</ArticleId></ArticleIdList></Reference><Reference><Citation>Masana L., Correig E., Ibarretxe D., Anoro E., Arroyo J. A., Jeric&#xf3; C., et al. (2021). Low HDL and high triglycerides predict COVID-19 severity. Sci. Rep. 11, 7217. 10.1038/s41598-021-86747-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-86747-5</ArticleId><ArticleId IdType="pmc">PMC8010012</ArticleId><ArticleId IdType="pubmed">33785815</ArticleId></ArticleIdList></Reference><Reference><Citation>Meacci E., Pierucci F., Garcia-Gil M. (2022). Skeletal muscle and COVID-19: The potential involvement of bioactive sphingolipids. Biomedicines 10, 1068. 10.3390/biomedicines10051068</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10051068</ArticleId><ArticleId IdType="pmc">PMC9138286</ArticleId><ArticleId IdType="pubmed">35625805</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina J., Van Der Velpen V., Teav T., Guitton Y., Gallart-Ayala H., Ivanisevic J. (2020). Single-step extraction coupled with targeted HILIC-MS/MS approach for comprehensive analysis of human plasma lipidome and polar metabolome. Metabolites 10, 495. 10.3390/metabo10120495</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/metabo10120495</ArticleId><ArticleId IdType="pmc">PMC7760228</ArticleId><ArticleId IdType="pubmed">33276464</ArticleId></ArticleIdList></Reference><Reference><Citation>Naviaux R. K. (2014). Metabolic features of the cell danger response. Mitochondrion 16, 7&#x2013;17. 10.1016/j.mito.2013.08.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mito.2013.08.006</ArticleId><ArticleId IdType="pubmed">23981537</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortona E., Malorni W. (2022). Long COVID: To investigate immunological mechanisms and sex/gender related aspects as fundamental steps for tailored therapy. Eur. Respir. J. 59, 2102245. 10.1183/13993003.02245-2021</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02245-2021</ArticleId><ArticleId IdType="pmc">PMC8462012</ArticleId><ArticleId IdType="pubmed">34531277</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov A. M., Shalagina M. N., Protopopov V. A., Sergeev V. G., Ovechkin S. V., Ovchinina N. G., et al. (2019). Changes in membrane ceramide pools in rat soleus muscle in response to short-term disuse. Int. J. Mol. Sci. 20, 4860. 10.3390/ijms20194860</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20194860</ArticleId><ArticleId IdType="pmc">PMC6801848</ArticleId><ArticleId IdType="pubmed">31574943</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C., Darley D. R., Wilson D. B., Howe A., Munier C. M. L., Patel S. K., et al. (2022). Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol. 23, 210&#x2013;216. 10.1038/s41590-021-01113-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Proto M. C., Fiore D., Piscopo C., Pagano C., Galgani M., Bruzzaniti S., et al. (2021). Lipid homeostasis and mevalonate pathway in COVID-19: Basic concepts and potential therapeutic targets. Prog. Lipid Res. 82, 101099. 10.1016/j.plipres.2021.101099</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.plipres.2021.101099</ArticleId><ArticleId IdType="pmc">PMC8074527</ArticleId><ArticleId IdType="pubmed">33915202</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiken S., Sittenfeld L., Dridi H., Liu Y., Liu X., Marks A. R. (2022). Alzheimer's-like signaling in brains of COVID-19 patients. Alzheimers Dement. 18, 955&#x2013;965. 10.1002/alz.12558</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12558</ArticleId><ArticleId IdType="pmc">PMC9011576</ArticleId><ArticleId IdType="pubmed">35112786</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrimpe-Rutledge A. C., Codreanu S. G., Sherrod S. D., Mclean J. A. (2016). Untargeted metabolomics strategies&#x2014;challenges and emerging directions. J. Am. Soc. Mass Spectrom. 27, 1897&#x2013;1905. 10.1007/s13361-016-1469-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13361-016-1469-y</ArticleId><ArticleId IdType="pmc">PMC5110944</ArticleId><ArticleId IdType="pubmed">27624161</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen B., Yi X., Sun Y., Bi X., Du J., Zhang C., et al. (2020). Proteomic and metabolomic characterization of COVID-19 patient sera. Cell 182, 59&#x2013;72.e15. 10.1016/j.cell.2020.05.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.05.032</ArticleId><ArticleId IdType="pmc">PMC7254001</ArticleId><ArticleId IdType="pubmed">32492406</ArticleId></ArticleIdList></Reference><Reference><Citation>So M., Kabata H., Fukunaga K., Takagi H., Kuno T. (2021). Radiological and functional lung sequelae of COVID-19: A systematic review and meta-analysis. BMC Pulm. Med. 21, 97. 10.1186/s12890-021-01463-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12890-021-01463-0</ArticleId><ArticleId IdType="pmc">PMC7983097</ArticleId><ArticleId IdType="pubmed">33752639</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J. B., Murthy S., Marshall J. C., Relan P., Diaz J. V. (2022). A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 22, e102&#x2013;e107. 10.1016/S1473-3099(21)00703-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J. T., Chen Z., Nie P., Ge H., Shen L., Yang F., et al. (2020). Lipid profile features and their associations with disease severity and mortality in patients with COVID-19. Front. Cardiovasc Med. 7, 584987. 10.3389/fcvm.2020.584987</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2020.584987</ArticleId><ArticleId IdType="pmc">PMC7746652</ArticleId><ArticleId IdType="pubmed">33344516</ArticleId></ArticleIdList></Reference><Reference><Citation>Trayssac M., Hannun Y. A., Obeid L. M. (2018). Role of sphingolipids in senescence: Implication in aging and age-related diseases. J. Clin. Invest. 128, 2702&#x2013;2712. 10.1172/JCI97949</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI97949</ArticleId><ArticleId IdType="pmc">PMC6025964</ArticleId><ArticleId IdType="pubmed">30108193</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Der Veen J. N., Kennelly J. P., Wan S., Vance J. E., Vance D. E., Jacobs R. L. (2017). The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease. Biochimica Biophysica Acta (BBA) - Biomembr. 1859, 1558&#x2013;1572. 10.1016/j.bbamem.2017.04.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamem.2017.04.006</ArticleId><ArticleId IdType="pubmed">28411170</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahlstr&#xf6;m A., Sayin S. I., Marschall H. U., B&#xe4;ckhed F. (2016). Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 24, 41&#x2013;50. 10.1016/j.cmet.2016.05.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2016.05.005</ArticleId><ArticleId IdType="pubmed">27320064</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerhuis J. A., Van Velzen E. J. J., Hoefsloot H. C. J., Smilde A. K. (2008). Discriminant Q2 (DQ2) for improved discrimination in PLSDA models. Metabolomics 4, 293&#x2013;296. 10.1007/s11306-008-0126-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11306-008-0126-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Who (2023). Clinical management of COVID-19: Living guideline. Geneva).</Citation><ArticleIdList><ArticleId IdType="pubmed">35917394</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q., Zhou L., Sun X., Yan Z., Hu C., Wu J., et al. (2017). Altered lipid metabolism in recovered SARS patients twelve years after infection. Sci. Rep. 7, 9110. 10.1038/s41598-017-09536-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-09536-z</ArticleId><ArticleId IdType="pmc">PMC5567209</ArticleId><ArticleId IdType="pubmed">28831119</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Xu E., Bowe B., Al-Aly Z. (2022). Long-term cardiovascular outcomes of COVID-19. Nat. Med. 28, 583&#x2013;590. 10.1038/s41591-022-01689-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong S. J. (2021). Long COVID or post-COVID-19 syndrome: Putative pathophysiology, risk factors, and treatments. Infect. Dis. (Lond) 53, 737&#x2013;754. 10.1080/23744235.2021.1924397</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2021.1924397</ArticleId><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu M., Liu Y., Xu D., Zhang R., Lan L., Xu H. (2020). Prediction of the development of pulmonary fibrosis using serial thin-section CT and clinical features in patients discharged after treatment for COVID-19 pneumonia. Korean J. Radiol. 21, 746&#x2013;755. 10.3348/kjr.2020.0215</Citation><ArticleIdList><ArticleId IdType="doi">10.3348/kjr.2020.0215</ArticleId><ArticleId IdType="pmc">PMC7231610</ArticleId><ArticleId IdType="pubmed">32410413</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J. Y., Qu F., Li J. F., Liu M., Ren F., Zhang J. Y., et al. (2016). Up-regulation of plasma hexosylceramide (d18: 1/18: 1) contributes to genotype 2 virus replication in chronic hepatitis C: A 20-year cohort study. Med. Baltim. 95, e3773. 10.1097/MD.0000000000003773</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000003773</ArticleId><ArticleId IdType="pmc">PMC4907656</ArticleId><ArticleId IdType="pubmed">27281078</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S., Luo P., Xu J., Yang L., Ma P., Tan X., et al. (2021). Plasma metabolomic profiles in recovered COVID-19 patients without previous underlying diseases 3 Months after discharge. J. Inflamm. Res. 14, 4485&#x2013;4501. 10.2147/JIR.S325853</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S325853</ArticleId><ArticleId IdType="pmc">PMC8434912</ArticleId><ArticleId IdType="pubmed">34522117</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinellu A., Paliogiannis P., Fois A. G., Solidoro P., Carru C., Mangoni A. A. (2021). Cholesterol and triglyceride concentrations, COVID-19 severity, and mortality: A systematic review and meta-analysis with meta-regression. Front. Public Health 9, 705916. 10.3389/fpubh.2021.705916</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2021.705916</ArticleId><ArticleId IdType="pmc">PMC8417431</ArticleId><ArticleId IdType="pubmed">34490188</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>